Nj State Employees Deferred Compensation Plan Viking Therapeutics, Inc. Transaction History
Nj State Employees Deferred Compensation Plan
- $789 Million
- Q2 2024
A detailed history of Nj State Employees Deferred Compensation Plan transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Nj State Employees Deferred Compensation Plan holds 38,000 shares of VKTX stock, worth $2.83 Million. This represents 0.26% of its overall portfolio holdings.
Number of Shares
38,000
Previous 8,700
336.78%
Holding current value
$2.83 Million
Previous $713,000
182.47%
% of portfolio
0.26%
Previous 0.09%
Shares
2 transactions
Others Institutions Holding VKTX
# of Institutions
464Shares Held
65.3MCall Options Held
6.24MPut Options Held
2.97M-
Vanguard Group Inc Valley Forge, PA10.1MShares$752 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$449 Million0.01% of portfolio
-
State Street Corp Boston, MA5.12MShares$382 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.25MShares$168 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$139 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $5.71B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...